
Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
“Site 7: Supply resilience alert: Management attention recommended.





